Concurrent Poster Spotlight Sessions 2, 6, 8, 9, 15
Session 2: Personalizing CDK 4/6 inhibitor therapy for patients with Metastatic Breast Cancer: Survival, QOL and biomarkers
Location: Hemisfair Ballroom 1-2
Moderator: Lisa Carey, Lineberger Comprehensive Cancer Center University of North Carolina
Poster Viewing 7:00-7:30
PS2-01: Dalpiciclib versus placebo in combination with letrozole or anastrozole as first-line treatment for women with HR+/HER2- advanced breast cancer: prespecified final analysis of progression-free survival of the phase 3 DAWNA-2 trial.
Binghe Xu, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
PS2-02: Tibremciclib (BPI-16350) plus fulvestrant versus placebo plus fulvestrant for patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: Updated analysis of the phase III study.
Xichun Hu, Fudan University Cancer Institute, Shanghai, China
PS2-03: Comparative overall survival of CDK4/6is plus an aromatase inhibitor (AI) in HR+/HER2- MBC in the US real-world setting.
Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
PS2-04: Health related quality of life with first- versus second-line CDK4/6 inhibitor use in advanced breast cancer: results from the phase 3 SONIA trial (BOOG 2017-03).
Noor Wortelboer, Erasmus University Medical Center, Rotterdam, Netherlands
PS2-05: PRESERVE 2: A randomized, phase 3, double-blind trial of trilaciclib or placebo in patients (pts) receiving first-line gemcitabine/carboplatin (GCb) for locally advanced or metastatic triple-negative breast cancer (mTNBC).
Shom Goel, University of Melbourne Peter MacCallum Cancer Centre, Melbourne, Australia
PS2-06: First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2- advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype & gene & signature expression.
Yen-Shen Lu, National Taiwan University Hospital, Taipei, Taiwan
PS2-07: Intrinsic Subtype at Progression to CDK4/6 Inhibitors Plus Endocrine Therapy in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer (MBC).
Francesco Schettini, Hospital Clinic Barcelona, Barcelona, Spain
PS2-08: Association of MammaPrint® with gene expression pathways predictive of resistance to cyclin-dependent kinase inhibition.
Adam Brufsky, University of Pittsburgh, Pittsburgh, Pennsylvania
PS2-09: Liquid biopsy DNADX assay in advanced ER+/HER2-negative breast cancer after progression on CDK4/6 and aromatase inhibitors: a correlative analysis from the PACE phase II randomized trial.
Guilherme Nader-Marta, Dana-Farber Cancer Institute, New York, New York
PS2-10: Integrating ctDNA and Tumor Fraction Features for Deciphering Molecular Response and Resistance Mechanism to Endocrine Therapy and CDK4/6 Inhibition in Advanced HR-positive Metastatic Breast Cancer.
Hao Liao, Peking University Cancer Hospital, Beijing, China
7:30-7:45 Discussant (PS2-01, PS2-02, PS2-03, PS2-04, PS2-05)
CDK 4/6i
Kari Wiskinski, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
7:45-8:00 Panel Q&A
8:00-8:15 Discussant (PS2-06, PS2-07, PS2-08, PS2-09, PS2-10)
Biomarkers
Matthew Goetz, Mayo Clinic, Rochester, Minnesota
8:15-8:30 Panel Q&A
Session 6: Locoregional Therapy
Location: Room 221ABC
Moderator: Mylin Torres, Winshop Cancer Institute of Emory University
PS6-01: The PARP inhibitor rucaparib is a strong radiosensitizer in women with residual triple-negative breast cancer treated concurrently with adjuvant radiotherapy.
Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York
PS6-02: Association of VMAT versus 3D-CRT Radiotherapy Treatment Technique with Acute Toxicity of Regional Nodal Irradiation: A Secondary Analysis of the SAPHIRe Phase III Randomized Clinical Trial.
Chelain Goodman, MD Anderson Cancer Center, Houston, Texas
PS6-03: Post-Mastectomy Proton Therapy Imparts Increased Risk of Capsular Contracture in Reconstructed Breast Cancer Patients.
Mehmet Murat Zerey, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
PS6-04: Eliminating breast surgery for invasive, hormone-positive breast cancers with an exceptional response to endocrine therapy and ablative radiotherapy: a single-arm, phase 2 trial.
Simona Shaitelman, MD Anderson Cancer Center, Houston, Texas
PS6-05: First report of clinicopathologic characteristics and surgical outcomes of patients in the Avoid axillary Sentinel Lymph node biopsy After Neoadjuvant chemotherapy (ASLAN) trial (KBCSG-28).
Han-Byoel Lee, Seoul National University College of Medicine, Seoul, South Korea
PS6-06: Upstage of N-Stage by Diagnostic Axillary Lymph Node Dissection in Patients w/ Isolated Tumor Cells or Micrometastases in Sentinel/Target Lymph Node after Neoadjuvant Chemotherapy - Results from the Prospective Multicenter AXSANA / EUBREAST 3 Study.
Thorsten Kuehn, University of Ulm, Germany
PS6-07: Clinical and patient reported outcomes in women offered oncoplastic breast conserving surgery as an alternative to mastectomy: 12-month results of the UK ANTHEM multicentre prospective cohort study.
Shelley Potter, University of Bristol Medical School, Bristol, United Kingdom
PS6-08: Quality of life following total mastectomy, breast-conserving surgery, and immediate breast reconstruction in patients with breast cancer: A multicenter cross-sectional study.
Hirohito Seki, Kyorin University School of Medicine, Mikita, Japan
7:30-7:45 Discussant (PS6-01, PS6-02, PS6-03, PS6-04)
Radiation Oncology
Erin Gillespie, University of Washington, Seattle, Washington
7:45-8:00 Panel Q&A
8:00-8:15 Discussant (PS6-05, PS6-06, PS6-07, PS6-08)
Biomarkers
Alastair Thompson, Baylor College of Medicine, Houston, Texas
8:15-8:30 Panel Q&A
Session 8: Novel HER2 Therapeutics
Location: Stars at Night 1-2
Moderator: Ian Krop, Yale School of Medicine
Poster Viewing 7:00-7:30
PS8-01: ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases..
Ethan (Di) Zhu, ZionPharma, Shanghai, China
PS8-02: A Phase 1 study Evaluating the Safety, Efficacy and Pharmacokinetics of TL938 in HER2-Positive Patients with Advance Solid Tumors.
Xiaoyang Xia, Wuhan Institute of Technology, Wuhan, China
PS8-03: Exploratory biomarker analysis of Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03).
William Jacot, Montpellier Cancer Institute and University of Montpellier, Montpellier, France
PS8-04: Targeting clinically advanced breast cancer with conjugated and unconjugated HER2 antibodies: Does copy number matter?
Nicole Odzer, Yale School of Medicine, New Haven, Connecticut
PS8-05: ACE-Breast-08: a phase I study of ARX788, a novel anti-HER2 antibody-drug conjugate, in patients with TKI pretreated HER2 positive advanced breast cancer.
Xiaojia Wang, Zhejiang Cancer Hospital, Hangzhou Institute of Medica(HIM) , Chinese Academy of Sciences, Zhejiang, China
PS8-06: A randomized, open-label phase III study comparing disitamab vedotin (an anti-HER2 monoclonal antibody-MMAE conjugate) with lapatinib plus capecitabine in patients with HER2-positive, advanced breast cancer with liver metastasis.
Binghe Xu, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
PS8-07: Efficacy and Safety of GQ1005, a Promising HER2-ADC, in Patients with Metastatic HER2-Positive Breast Cancer.
Biyun Wang, Fudan University Shanghai Cancer Center, Shanghai, China
PS8-08: Efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate (ADC), in 391 heavily pretreated multiple solid tumors with HER2-expression or mutations: a global, multi-center, first-in-human, phase 1 study.
Herui Yao, Sun Yat-Sen University, Guangzhou, China
PS8-09: Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study.
Alberto Montero, University Hospitals Cleveland Medical Center, Cleveland, Ohio
7:30-7:45 Discussant (PS8-01, PS8-02, PS8-03, PS8-04)
Radiation Oncology
Paolo Tarantino, Dana-Farber Cancer Institute, Boston, Massachusetts
7:45-8:00 Panel Q&A
8:00-8:15 Discussant (PS8-05, PS8-06, PS8-07, PS8-08, PS8-09)
Biomarkers
Mafalda Oliveira, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
8:15-8:30 Panel Q&A
Session 9: ctDNA uses for Minimal Residual Disease testing, tumor evolution, and novel technologies
Location: Stars at Night 3-4
Moderator: Charles Perou, Lineberger Comprehensive Cancer Center University of North Carolina
Poster Viewing 7:00-7:30
PS9-01: Actionable Genomic Alterations in Localized Hormone Receptor Positive (HR+) Breast Cancer and Impact on Clinical Outcomes: Results from Comprehensive Whole Exome Sequencing (WES) and Tumor-Informed circulating tumor DNA (ctDNA) analysis.
Marla Lipsyc-Sharf, UCLA Health, Santa Monica, California
PS9-02: Serial circulating tumor DNA (ctDNA) assessment to predict treatment response and identify genomic evolution in patients with metastatic breast cancer (mBC).
Laura Linville, Johns Hopkins Kimmel Cancer Center, Washington, D.C.
PS9-03: Circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study.
Eleanor Taranto, University of Pennsylvania, Philadelphia, Pennsylvania
PS9-04: Evaluating racial genomic differences in de novo metastatic breast cancer utilizing ctDNA: results from a large multi-center consortium.
Emily Podany, Washington University School of Medicine, St. Louis, Missouri
PS9-05: Somatic Structural Variation in Breast Cancer and its Application in Longitudinal Analysis of Circulating Tumor DNA in Early Breast Cancer.
Mitchell Elliott, University of Toronto, Toronto, Canada
PS9-06: Tracking structural variants in ctDNA using a high-sensitivity assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.
Hervé Bonnefoi, Bordeaux Institute of Oncology, Bordeaux, France
PS9-07: Epigenomic Characterization of ER Transcriptional Activation via Liquid Biopsy.
Jonathan Beagan, Precede Biosciences, Boston, Massachusetts
PS9-08: Ultra-sensitive detection of circulating tumor DNA (ctDNA) in patients (pts) undergoing neoadjuvant endocrine therapy for hormone receptor-positive (HR+) early breast cancer (BC).
Albert Grinshpun, Dana-Farber Cancer Institute, Boston, Massachusetts
7:30-7:45 Discussant (PS9-01, PS9-03, PS9-04, PS9-06)
Evaluating Minimal Residual Disease
Yara Abdou, University of North Carolina School of Medicine, Chapel Hill, North Carolina
7:45-8:00 Panel Q&A
8:00-8:15 Discussant (PS9-02, 9-05, PS6-07, PS9-08)
ctDNA in tumor evolution
Marija Balic, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania
8:15-8:30 Panel Q&A
Session 15: Survivorship – Biomarker predictors and other survival-associated factors
Location: Hemisfair Ballroom 3
Moderator: Lindsay Peterson, Washington University Siteman Cancer Center, St. Louis, Missouri
Poster Viewing 7:00-7:30
PS15-01: Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer.
Margaux Wooster, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York
PS15-02: Genome-wide association study (GWAS) of aromatase inhibitor musculoskeletal toxicity (AIMT) among early-stage breast cancer (BC) survivors.
Pietro Lapidari, Institut de Cancérologie Gustave Roussy, Villejuif, France
PS15-03: Retrospective study of GLP-1 Receptor Agonists in Breast Cancer Survivors: Weight Loss and Patient Outcomes
Jasmine Sukumar, MD Anderson Cancer Center, Houston, Texas
PS15-04: Impact of a dietitian and nurse-led survivorship clinic utilizing ePRO collection on body composition and muscle strength in early-stage breast cancer: Results from the Linking You to Support and Advice (LYSA) Randomized Control Trial.
Katie E. Johnston, University College Cork, Cork, Ireland
PS15-05: Breast Cancer Patients with High-Risk Disease Characteristics have Proportionately Higher Risk of Mortality from Non-Breast Cancer Related Causes in both Non-Metastatic and Metastatic Disease.
Shipra Gandhi, Roswell Park Comprehensive Cancer Center, Buffalo, New York
PS15-06: Ability to comply with placebo predicts overall survival in randomized trial.
Tara Sanft, Yale School of Medicine, New Haven, Connecticut
PS15-07: Late effects of chemotherapy on patient-reported falls among older breast cancer survivors.
Inimfon Jackson, MD Anderson Cancer Center, Houston, Texas
PS15-08: Factors and trends associated with alcohol intake in late survivorship for patients with breast cancer.
Sanjna Rajput, Mayo Clinic, Rochester, Minnesota
7:30-7:45 Discussant (PS15-01, PS15-02, PS15-03, PS15-04)
Weight and Biomarkers
Neil Iyengar, Memorial Sloan Kettering Cancer Center, New York, New York
7:45-8:00 Panel Q&A
8:00-8:15 Discussant (PS15-05, PS15-06, PS15-07, PS15-08)
Predictors of Survival
Maryam Lustberg, Yale University, New Haven, Connecticut
8:15-8:30 Panel Q&A
|